Andy

ROCKVILLE, M.D. and SUZHOU, China, Dec. 6, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, today announces the licensing deal expansion with Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index.

The expanded deal builds on a previous agreement signed in June 2021, under which Innovent is granted to deploy Synaffix’s ADC technologies on a target-specific, non-exclusive basis, including GlycoConnect®, HydraSpace® and one of its toxSYN® linker-payloads, for a therapeutic molecule (Innovent R&D code: IBI343, a CLDN18.2 ADC) which has advanced to Phase 1 clinical development.

A powerful web app to help drug designers accurately predict the pKa value of titratable residues

December 5, 2023, Baltimore, MD – ComputChem, an Early Charm company that develops computational chemistry software for drug design, has just launched its first product, iTitrate.

iTitrate is a web app that accurately predicts the pKa values of titratable residues by simulating an acid-base titration experiment. It computationally allows a protein to adjust its protonation and conformational states to solution pH. This state-of-the-art approach has been rigorously validated through references available on the ComputChem website.

WASHINGTON, Dec. 6, 2023 /PRNewswire/ — Danaher Corporation (NYSE:DHR) (“Danaher”) announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) (“Abcam”).

The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the “Scheme”) and the Scheme became effective in accordance with its terms on December 6, 2023. As a result, Abcam has become an indirect wholly owned subsidiary of Danaher. Trading of Abcam ADSs on Nasdaq has been suspended.

By Pratik Jain and Khushi Mandowara – Dec 5 (Reuters) – Weight-loss drug developer Altimmune (ALT.O) is open to deals and collaborations with large drugmakers as it actively looks for partners to launch and develop its experimental obesity drug, CEO Vipin Garg told Reuters on Tuesday.

Upbeat mid-stage trial data for its obesity drug and recent multi-billion dollar deals by companies such as Roche (ROG.S) and AstraZeneca (AZN.L) to grab a slice of the fast-growing market have fueled hopes of Big Pharma scooping up the company.

Gaithersburg, Maryland-based Altimmune last week reported mid-stage trial data for pemvidutide that showed the drug helped reduce weight by 15.6% on average and continued weight loss at the end of treatment.

MENLO PARK, Calif., Dec. 4, 2023 /PRNewswire/ — Enavate Sciences, a portfolio company of Patient Square Capital, is pleased to announce that Sara M. Nayeem, M.D. has joined the firm as Executive Vice President, Investments. Dr. Nayeem reports to James Boylan, Chief Executive Officer of Enavate Sciences, and will serve an integral role in the origination, evaluation, and selection of Enavate investments, as well as support Enavate partner companies on governance, partnerships, fundraising, and other strategic initiatives.

Dr. Nayeem has 20 years of banking and institutional investing experience. She most recently served as Partner at Avoro Ventures, a biopharma venture fund she helped launch in 2021. Previously she was a Partner at New Enterprise Associates, Inc. (NEA), where she spent 12 years as part of the biopharma investing group. Prior to joining NEA, Dr. Nayeem was an Associate with Merrill Lynch’s Global Healthcare Group, where she advised biotechnology and medical device companies. She began her career as an Investment Banking Analyst at Morgan Stanley.

AI Simulation on MIRA1a Showcases Significant Potential Advantages Over Plant-Based Medical Marijuana Related to Anxiety, Appetite and Cognition

BALTIMORE, Dec. 4, 2023 /PRNewswire/ — MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), an innovative pre-clinical-stage pharmaceutical company focused on neurologic and neuropsychiatric disorders, has released new data from artificial intelligence (AI) simulations that show that, compared to plant-based medical marijuana, there may be significant potential advantages to the therapeutic potential of MIRA1a, such as its potential to offer a superior anti-anxiety treatment, increased cognition and without the increased appetite associated with THC.

The simulations on MIRA1a were conducted in conjunction with the Company’s strategic collaboration with InSilicoTrials, a company specializing in leveraging AI and simulations to enhance drug and medical device development.